Phathom Q3 2026 slides: profitability milestone, 71% revenue growth
Phathom Pharmaceuticals (PHAT) reported Q3 2026 earnings with $84.7M revenue (71% YoY growth) and $2.1M net cash, slightly missing analyst estimates. The company achieved profitability and strong prescription growth for VOQUEZNA, its lead product. Stock rose 8.03% premarket. Management reaffirmed full-year guidance and expects sustained profitability.
How this was made
The 30-second read
Why it matters
The earnings beat and profitability milestone suggest near‑term upside, but guidance remains modest and future trial data remain a risk.
Market read
Strong earnings beat and cash flow generation provide a fresh catalyst for PHAT, likely prompting short‑term buying interest.
What to watch
Upcoming Phase II data and cash‑flow outlook for 2027 could moderate enthusiasm if results disappoint.
Background
Phathom Pharmaceuticals (NASDAQ:PHAT) announced Q3 2026 results, highlighting a 71% YoY revenue increase, operating profit, and cash generation.
Ticker impact
Phathom Pharmaceuticals reported Q3 2026 earnings with 71% revenue growth, an EPS beat and a second consecutive quarter of operating profit.
upward pressure as investors price in the earnings beat and cash generation.
The company posted a $0.04 adjusted EPS versus a $0.10 loss estimate and the stock rose 8% pre‑market, indicating strong market reaction.
Market effects
Positive earnings may lift the broader biotech and gastroenterology therapeutic sector.
US biotech investors may see increased risk appetite for similar small‑cap pipelines.
Limited to investors tracking US‑listed biotech stocks.
Counterpoint
If the revenue miss relative to consensus signals demand softness, the rally could be short‑lived.
Key entities
- companyPhathom Pharmaceuticals
US‑listed biotech focused on GERD treatment VOQUEZNA.
- partnerBlinkRx
Copay‑assistance partner for VOQUEZNA.



